5006802024-10-012025-03-315006802025-03-315006802024-03-315006802024-04-012025-03-315006802024-10-012025-03-31in-capmkt:OtherExpenses1Member5006802024-04-012025-03-31in-capmkt:OtherExpenses1Member5006802024-10-012025-03-31RelatedPartyTransactionDomain15006802024-09-30RelatedPartyTransactionDomain15006802025-03-31RelatedPartyTransactionDomain15006802024-10-012025-03-31RelatedPartyTransactionDomain25006802024-09-30RelatedPartyTransactionDomain25006802025-03-31RelatedPartyTransactionDomain25006802024-10-012025-03-31RelatedPartyTransactionDomain35006802024-09-30RelatedPartyTransactionDomain35006802025-03-31RelatedPartyTransactionDomain35006802024-10-012025-03-31RelatedPartyTransactionDomain45006802024-09-30RelatedPartyTransactionDomain45006802025-03-31RelatedPartyTransactionDomain45006802024-10-012025-03-31RelatedPartyTransactionDomain55006802024-09-30RelatedPartyTransactionDomain55006802025-03-31RelatedPartyTransactionDomain55006802024-10-012025-03-31RelatedPartyTransactionDomain65006802024-09-30RelatedPartyTransactionDomain65006802025-03-31RelatedPartyTransactionDomain65006802024-10-012025-03-31RelatedPartyTransactionDomain75006802024-09-30RelatedPartyTransactionDomain75006802025-03-31RelatedPartyTransactionDomain75006802024-10-012025-03-31RelatedPartyTransactionDomain85006802024-09-30RelatedPartyTransactionDomain85006802025-03-31RelatedPartyTransactionDomain85006802024-10-012025-03-31RelatedPartyTransactionDomain95006802024-09-30RelatedPartyTransactionDomain95006802025-03-31RelatedPartyTransactionDomain95006802024-10-012025-03-31RelatedPartyTransactionDomain105006802024-09-30RelatedPartyTransactionDomain105006802025-03-31RelatedPartyTransactionDomain105006802024-10-012025-03-31RelatedPartyTransactionDomain115006802024-09-30RelatedPartyTransactionDomain115006802025-03-31RelatedPartyTransactionDomain115006802024-10-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares500680PFIZERNAINE182A01018PFIZER LIMITEDMain BoardEquity2024-04-012025-03-312025-05-192025-05-13INRCroresHalf YearlyYearlySingle segmentPharmaceuticals2025-05-1912:15:002025-05-1919:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-01-31www.pfizerltd.co.infalsefalseNot Applicable2024-10-012025-03-31AuditedStandalone591910000044580000063649000007064000001395200000-76800000829100000269000001640000007902000003835000000252990000017281000004258000000990600000-4200000094860000003309400000000033094000002350000033329000004575000001072.3472.340072.3472.341. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of <BR> Directors at their meeting held on May 19, 2025. <BR> <BR> 2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards <BR> Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and <BR> in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 as amended from time to time. <BR> <BR> 3. The financial results for the year ended March 31, 2025 have been audited by the statutory auditors of the <BR> Company. The audit opinion does not contain any modifications. The audit report will be filed with the Stock <BR> Exchanges and will also be available on the Company's website - www.pfizerltd.co.in <BR> <BR> 4. Figures for the quarter ended March 31, 2025 and March 31, 2024 represent the difference between the <BR> audited figures in respect of the full financial year and published unaudited figures of nine months ended <BR> December 31, 2024 and December 31, 2023 respectively which were subject to a limited review by the <BR> statutory auditors. <BR> <BR> 5. Exceptional item <BR> <BR> In the previous year the Company had entered into an agreement to assign and assume the Lease <BR> of MIDC Land and Sale of Building constructed on such land for transferring and assigning Pfizer <BR> unexpired leasehold rights in the land situated at Thane and sale of structures and buildings <BR> constructed thereon, to Zoetis Pharmaceutical Research Private Limited, for a lumpsum <BR> consideration of Rs. 264.40 crore, of which Rs. 52.88 crore had been received as an advance. The said <BR> assets were classified as held for sale. During the quarter ended 31 March 2025 the Company has <BR> received requisite approvals from MIDC and has completed the transfer and sale of said assets. Net <BR> gain of Rs. 172.81 crore net of carrying value of Rs. 31.75 crore and cost to sell Premium and other <BR> charges Rs. 59.84 crore net of recovery is disclosed as an Exceptional items in the financial results. <BR> <BR> For the year ended March 31, 2024, the exceptional item is in relation to provision for old pending <BR> VAT CST litigations. The Company opted for Maharashtra VAT Amnesty Scheme for certain years <BR> and had received final settlement orders. Pursuant to the said orders, the Company had written back <BR> an excess provision of Rs. 7 .95 crore. <BR> <BR> 6. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments <BR> is not applicable and accordingly not made. <BR> <BR> 7. The Board of Directors have recommended a final dividend of Rs. 35 per equity share of Rs. 10 each 350% and a special dividend of Rs. 100 per equity share of Rs. 10 each 1000 in view of 75th year of Pfizer in India and a special dividend of Rs. 30 per equity share of Rs. 10 each 300 in view of the gain on transfer of assignment of leasehold land and building constructed on such land thereon, totaling to a dividend of Rs.165 per equity share of Rs. 10 each for the financial year ended March 31, 2025. These proposed dividends amounting to Rs. 754.84 crore are subject to the approval ofthe shareholders in the annual general meeting. <BR> <BR> 8.The Company does not have any subsidiary company or associate company or joint venture company as at <BR> March 31, 2025.2024-04-012025-03-31AuditedStandalone228135000001722500000245360000002723400000512750000025360000037133000008410000060790000035934000001610320000084328000001728100000101609000002641000000-1561000002484900000076760000000000767600000074000007683400000457500000100167.79167.7900167.79167.79Other Expenses790200000Other Expenses359340000017182000007640000005274900000243100000000000139300000139300000693000000583770000013982600000475920000001930900000495070000023059100000039000000299797000000389600000351285000004911110000045750000041716600000421741000004217410000000006762000006762000005657000000001241900000250000001127000001403300000151600000078350000023245000006476000005134000002209600000056951000000069370000004911110000084100000-422200000-6820000000676100000000-15310000002194000000607900000003159000000021000000013660000000-1728100000-9900000000-428500000973240000000-157270000015622000000659750000000000000200000028150000000000000000151680000000000013936000000-3344300000-71340000000000000004479000001602500000300000000-205340000038307000000383070000011200000004950700000-31400000-990000079000002500000235000007400000Pfizer Limited******Pfizer Service Company BVBA, Belgium******Fellow SubsidiaryPurchase of goods or services2809600000On arms length basis and in Ordinary course of business02024-05-172809600000564400000219000000Pfizer Limited******Pfizer Products India Private Limited, India******Fellow SubsidiarySale of goods or services253100000On arms length basis and in Ordinary course of business02024-05-17253100000-178100000-267000000Pfizer Limited******Pfizer export B.V******Fellow SubsidiarySale of goods or services23000000On arms length basis and in Ordinary course of business02024-05-1723000000-14000000-19600000Pfizer Limited******Pfizer Worldwide Services Company******Fellow SubsidiarySale of goods or services492700000On arms length basis and in Ordinary course of business02024-05-17492700000-396000000-215200000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiarySale of goods or services19600000On arms length basis and in Ordinary course of business02024-05-1719600000-21100000-13300000Pfizer Limited******Pfizer Products India Private Limited, India******Fellow SubsidiaryAny other transactionService Income/Recovery of expenses400000On arms length basis and in Ordinary course of business02024-05-174000000-400000Pfizer Limited******John Wyeth & Brothers Ltd******Companies holding significant incfluenceAny other transactionRecovery of Expenses400000On arms length basis and in Ordinary course of business02024-05-174000000-400000Pfizer Limited******Pfizer Products India Private Limited, India******Fellow SubsidiaryAny other transactionService Charges, Reimbursement of expenses0On arms length basis and in Ordinary course of business02024-05-17000Pfizer Limited******Pfizer Products India Private Limited, India******Fellow SubsidiaryAny other transactionService Charges, Reimbursement of expenses15100000On arms length basis and in Ordinary course of business02024-05-1715100000015100000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiaryAny other transactionService Income1000000On arms length basis and in Ordinary course of business02024-05-17100000001000000Pfizer Limited******John Wyeth & Brothers Ltd******Companies holding significant incfluenceAny other transactionRecovery of Expenses0On arms length basis and in Ordinary course of business02024-05-17025000000250000003614900000AuditedtrueB S R & Co. LLPtrue2025-07-31